Difference Between Astrazeneca and Pfizer

The AstraZeneca and Pfizer COVID-19 vaccines differ in composition, technology, efficacy, side effects, and logistics. AstraZeneca's Covishield uses a chimpanzee adenovirus vector, while Pfizer's Comirnaty employs mRNA technology. Covishield can be stored at standard refrigeration temperatures, whereas Comirnaty requires ultra-cold storage. Both vaccines have demonstrated high efficacy in preventing severe illness and hospitalization, with comparable side effects profiles. The distinct storage requirements greatly influence their distribution networks, with Covishield being more suitable for regions with limited resources. As we examine the nuances of each vaccine, the complexities of their development and rollout come into sharp focus.

Development and Approval Process

Pfizer and AstraZeneca, two pharmaceutical giants, undertook a rigorous development and approval process for their COVID-19 vaccines, traversing a complex regulatory landscape to bring their life-saving products to the global market.

The development process involved overcoming significant regulatory hurdles, including securing approvals from regulatory agencies such as the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

To confirm the safety and efficacy of their vaccines, both companies conducted extensive clinical trials, involving thousands of participants, to gather robust data on the vaccines' performance.

These trials were meticulously designed to assess the vaccines' ability to prevent severe illness, hospitalization, and death from COVID-19.

The data generated from these trials formed the basis of the companies' applications for emergency use authorization, which were eventually granted by regulatory agencies, paving the way for the vaccines' widespread distribution.

Throughout the development and approval process, Pfizer and AstraZeneca demonstrated their commitment to upholding the highest standards of quality, safety, and efficacy.

Vaccine Composition and Technology

At the core of AstraZeneca and Pfizer's COVID-19 vaccines lies a sophisticated composition and technology that has enabled the development of effective and safe immunization against the SARS-CoV-2 virus.

The vaccines' composition is characterized by a unique blend of ingredients, including antigens, adjuvants, and preservatives. The adjuvant role in the vaccines is vital, as it strengthens the immune response, allowing for a stronger and more durable defense against the virus.

AstraZeneca's vaccine, Covishield, is based on a chimpanzee adenovirus vector, which carries genetic material from the SARS-CoV-2 spike protein. This vector-based technology enables the vaccine to induce a robust immune response.

In contrast, Pfizer's vaccine, Comirnaty, employs mRNA technology, which involves the use of messenger RNA (mRNA) to instruct cells to produce the SARS-CoV-2 spike protein.

The mRNA stability in Comirnaty is secured through the use of lipid nanoparticles, which protect the mRNA from degradation and facilitate its uptake by immune cells.

These distinct approaches have led to the development of two highly effective vaccines, each with its unique characteristics and advantages.

Efficacy and Side Effects Profile

Both AstraZeneca's Covishield and Pfizer's Comirnaty have demonstrated remarkable efficacy in preventing severe illness and hospitalization due to COVID-19, while also exhibiting a generally favorable side effects profile.

The immune response triggered by both vaccines has been shown to be robust, with a strong antibody response observed in clinical trials. Age factors have also been taken into consideration, with both vaccines demonstrating efficacy across various age groups.

Some key aspects of their efficacy and side effects profile include:

Efficacy rates of 76% and 95% against severe illness and hospitalization, respectively, for Covishield, and 95% for Comirnaty.

Mild to moderate side effects, such as pain, redness, and swelling at the injection site, as well as fatigue, headache, and muscle pain.

A low incidence of serious adverse events, with no significant differences observed between the two vaccines.

A strong immune response, with high levels of neutralizing antibodies observed in clinical trials.

Efficacy maintained across various age groups, including older adults and those with underlying health conditions.

Storage and Distribution Logistics

The complex storage and distribution logistics of Covishield and Comirnaty significantly impact their widespread adoption and accessibility.

The answer lies in their distinct storage requirements, which greatly influence their distribution networks.

Covishield, the AstraZeneca vaccine, can be stored at standard refrigeration temperatures (2-8°C) for up to six months, making it more feasible for widespread distribution, particularly in developing regions with limited cold chain infrastructure.

In contrast, Comirnaty, the Pfizer-BioNTech vaccine, requires ultra-cold storage at -70°C, necessitating a more specialized and costly cold chain.

This distinction has profound implications for supply networks, as Comirnaty's storage requirements demand a more sophisticated and expensive logistics infrastructure.

As a result, Covishield's more flexible storage requirements make it a more viable option for regions with limited resources, while Comirnaty's strict storage conditions restrict its accessibility in these areas.

Understanding these differences is vital for effective vaccine distribution and accessibility.

Global Rollout and Accessibility

The disparate storage requirements of Covishield and Comirnaty have far-reaching implications for their global rollout, with the former's flexibility facilitating broader accessibility in resource-constrained regions.

This disparity has significant equity concerns, as regions with limited infrastructure may struggle to store and distribute Comirnaty, exacerbating regional disparities in vaccine access.

Key factors influencing global rollout and accessibility include:

  • Temperature control: Covishield can be stored at 2-8°C, whereas Comirnaty requires -70°C, making the latter more challenging to transport and store.
  • Cold chain infrastructure: Regions with limited cold chain infrastructure may struggle to maintain the required temperatures for Comirnaty, hindering its distribution.
  • Logistics and transportation: The need for ultra-cold storage and transportation increases the complexity and cost of distributing Comirnaty.
  • Regional storage capacity: Limited storage capacity in resource-constrained regions may necessitate multiple shipments, increasing the risk of vaccine spoilage and wastage.
  • Vaccine allocation: The distribution of vaccines may be influenced by political and economic factors, further exacerbating regional disparities in vaccine access.


Development and Approval Process

AstraZeneca and Pfizer-BioNTech vaccines underwent different development and approval processes.

AstraZeneca's vaccine was developed in collaboration with the University of Oxford, while Pfizer-BioNTech developed its vaccine in partnership with BioNTech.

AstraZeneca's vaccine received emergency approval from the European Medicines Agency (EMA) in January 2021, whereas Pfizer-BioNTech's vaccine received approval in December 2020.

Vaccine Composition and Technology

AstraZeneca's vaccine uses a chimpanzee adenovirus vector, whereas Pfizer-BioNTech's vaccine employs mRNA technology.

The AstraZeneca vaccine is a viral vector-based vaccine, using a weakened virus to deliver genetic material to cells.

In contrast, Pfizer-BioNTech's vaccine uses messenger RNA (mRNA) to instruct cells to produce a protein, triggering an immune response.

Efficacy and Side Effects Profile

Both vaccines have demonstrated high efficacy in preventing severe COVID-19 cases.

AstraZeneca's vaccine has shown a general efficacy of 76% against symptomatic COVID-19, while Pfizer-BioNTech's vaccine has demonstrated an efficacy of 95%.

Common side effects for both vaccines include pain, redness, and swelling at the injection site, as well as fatigue, headache, and muscle pain.

Storage and Distribution Logistics

AstraZeneca's vaccine can be stored at normal refrigerator temperatures (2-8°C), making it more accessible to developing countries.

Pfizer-BioNTech's vaccine, on the other hand, requires ultra-cold storage (-70°C) for long-term storage and transportation, posing logistical challenges.

Global Rollout and Accessibility

Both vaccines have been distributed globally, with AstraZeneca's vaccine being more accessible to low- and middle-income countries due to its easier storage requirements and lower cost.

Pfizer-BioNTech's vaccine has been primarily distributed in high-income countries.


The AstraZeneca and Pfizer-BioNTech vaccines differ in their development, composition, efficacy, and logistics.

Understanding these differences is vital for informed decision-making in the global response to the COVID-19 pandemic.

Sharing Is Caring: